2024 ICD-10-CM Diagnosis Code E34.328

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

• 46,XX ovarian dysgenesis, short stature syndrome
• 46,XY disorder of sex development
• Asexual dwarfism
• Asexual dwarfism
• Autosomal recessive asexual dwarfism
• Bone age finding
• Congenital anomaly of endocrine ovary
• Congenital hypoplasia of adrenal gland
• Congenital stenosis of carotid artery
• Delayed bone age
• Dolichocephalic dwarfism
• DONSON-related microcephaly, short stature, limb abnormalities spectrum
• Glucose-galactose malabsorption
• Glucose-galactose malabsorption
• Hereditary acantholytic dermatosis
• Infantile dwarf
• Insulin resistance
• Insulin resistance
• Internal carotid artery stenosis
• Intrauterine growth restriction, short stature, early adult-onset diabetes syndrome
• Keratosis follicularis, dwarfism, cerebral atrophy syndrome
• Long narrow head
• Malabsorption of glucose
• Malabsorption of glucose
• Microcephalic osteodysplastic primordial dwarfism type II
• Microcephalic osteodysplastic primordial dwarfism types I and III
• Microcephalic primordial dwarfism Alazami type
• Microcephalic primordial dwarfism Dauber type
• Microcephalic primordial dwarfism due to ZNF335 deficiency
• Microcephalic primordial dwarfism Montreal type
• Microcephalic primordial dwarfism Toriello type
• Microcephalic primordial dwarfism, insulin resistance syndrome
• Microcephalus, hypergonadotropic hypogonadism, short stature syndrome
• MIRAGE syndrome
• Moyamoya angiopathy, short stature, facial dysmorphism, hypergonadotropic hypogonadism syndrome
• Moyamoya disease
• Multiple malformation syndrome, moderate short stature, facial
• Osteodysplastic primordial dwarfism
• Osteodysplastic primordial dwarfism
• Ovarian dysgenesis
• Primordial dwarfism
• Short stature co-occurrent and due to endocrine disorder
• Short stature co-occurrent and due to endocrine disorder
• Short stature co-occurrent and due to endocrine disorder
• Short stature due to growth hormone secretagogue receptor deficiency
• Short stature with delayed bone age due to thyroid hormone metabolism deficiency
• Short stature, unique facies, enamel hypoplasia, progressive joint stiffness, high-pitched voice syndrome
• Short stature, wormian bones, dextrocardia syndrome
• X-linked asexual dwarfism

Clinical Information

• Moyamoya Disease

  a noninflammatory, progressive occlusion of the intracranial carotid arteries and the formation of netlike collateral arteries arising from the circle of willis. cerebral angiogram shows the puff-of-smoke (moyamoya) collaterals at the base of the brain. it is characterized by endothelial hyperplasia and fibrosis with thickening of arterial walls. this disease primarily affects children but can also occur in adults.

• Insulin Resistance

  diminished effectiveness of insulin in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent hyperglycemia or ketosis.

• Metabolic Syndrome

  a cluster of symptoms that are risk factors for cardiovascular diseases and type 2 diabetes mellitus. the major components of metabolic syndrome include abdominal obesity; atherogenic dyslipidemia; hypertension; hyperglycemia; insulin resistance; a proinflammatory state; and a prothrombotic (thrombosis) state.

• Moyamoya Disease

  a rare inherited vascular disorder characterized by constriction of arteries at the base of the brain, resulting in the formation of collateral circulation in order to compensate for the constriction. the name "moyamoya" in japanese means "puff of smoke" and derives from the characteristic radiographic appearance of the collateral vessels.

• Moyamoya Disease 2|MYMY2

  an autosomally inherited subtype of moyamoya disease often presenting in childhood caused by mutation(s) in the rnf213 gene, encoding e3 ubiquitin-protein ligase rnf213.

• RNF213 wt Allele|ALK Lymphoma Oligomerization Partner on Chromosome 17 Gene|ALO17|C17orf27|Chromosome 17 Open Reading Frame 27 Gene|DKFZp762N1115|FLJ13051|KIAA1554|KIAA1618|MGC46622|MGC9929|MYMY2|MYSTR|Moyamoya Disease 2 Gene|NET57|Ring Finger Protein 213 wt Allele|hCG_1812857

  human rnf213 wild-type allele is located in the vicinity of 17q25.3 and is approximately 135 kb in length. this allele, which encodes e3 ubiquitin-protein ligase rnf213 protein, may play a role in the regulation of protein ubiquitination. a chromosomal translocation t(2;17)(p23;q25) of this gene with the alk gene is associated with anaplastic large cell lymphoma.

• Homeostatic Model Assessment of Insulin Resistance

  an assessment of beta-cell function and insulin resistance based on fasting blood glucose and insulin concentrations.

• Hyperandrogenism, Insulin Resistance, Acanthosis Nigricans Syndrome|HAIR-AN Syndrome

  a condition characterized by hyperandrogenism, insulin resistance, and acanthosis nigricans, typically associated with obesity in teenage girls. it is considered to be a subtype of polycystic ovarian syndrome, but may occur in male individuals. etiology is unclear, but some cases may be associated with mutations affecting the tyrosine kinase domain of the insulin receptor.

• Insulin Receptor Mutation - Associated Insulin Resistance Syndromes

  insulin resistance caused by inactivating mutation(s) in the insr gene encoding the insulin receptor.

• Insulin Resistance

  decreased sensitivity to circulating insulin which may result in acanthosis nigicrans, elevated insulin level or hyperglycemia.

• Insulin Resistance Measurement|INSULINR|Insulin Resistance|Insulin Resistance

  the determination of the insulin resistance (cells inability to respond to insulin) in a biological specimen.

• Insulin Resistance Syndrome

  a cluster of closely related metabolic abnormalities associated with insulin resistance that confer an increased risk of the development of type 2 diabetes and cardiovascular disease. these abnormalities may include obesity, high blood pressure, abnormal cholesterol levels, proteinuria, and/or polycystic ovary syndrome.

• Insulin Resistant Diabetes Mellitus with Acanthosis Nigricans and Hyperandrogenism|Type A Insulin Resistance Syndrome

  a syndrome of insulin resistance caused by mutation(s) in the insr gene, encoding the insulin receptor. this condition is characterized by a clinical triad of hyperinsulinemia, acanthosis nigricans, and hyperandrogenism without lipodystrophy. this is the least severe of a spectrum of disorders; the other two conditions are rabson-mendenhall syndrome and donohoe syndrome.

• Obesity-Associated Insulin Resistance

  insulin resistance associated with obesity, which may be attributed in part to impaired insulin signaling in target tissues, or impaired insulin-stimulated glucose transport due to reduced expression of the glucose transporter protein 4.

E34.328 is grouped with Diagnostic Related Groups - MS-DRG Mapping

Diagnostic Related Groups (DRGs) are a classification system used to group together diagnosis codes for the purpose of reimbursement and healthcare management. DRGs are used to standardize the way hospitals and other providers are paid for inpatient services. In this system patients are grouped together based on their principal diagnosis in areas referred to as Major Diagnostic Categories (MDC). Once a patient is assigned a particular diagnostic category, providers receive a predetermined payment rate for the services rendered. This reimbursement rate is often fixed and is meant to cover the cost of care for that patient. Reimbursement is also affected by the relative weight of a diagnostic related group based on the severity of a patient's illness and the associated cost of care during hospitalization.

Diagnostic related groups encourage healthcare providers to focus on quality and efficiency in patient care while managing costs effectively. The diagnosis code is present in the following groups for version MS-DRG V41.0 applicable from 10/01/2023 through 09/30/2024.

The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.

Replacement Code

E34328 replaces the following previously assigned ICD-10-CM code(s):

• E34.3 - Short stature due to endocrine disorder

Code History

• FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
• FY 2023 - Code Added, effective from 10/1/2022 through 9/30/2023